Current possibilities of clinical applications of breast tumors typing expression
Vol. 62 No. 1 (2016), Articles
Vol. 62 No. 1 (2016)

Current possibilities of clinical applications of breast tumors typing expression

Articles
https://doi.org/10.37469/0507-3758-2016-62-1-31-34
Published 15.12.2016
St. Petersburg Clinical Scientific-Practical Center of Special Types of Medical Care (Oncology); St. Petersburg National Research Academic University of Russian Academy of Sciences
St. Petersburg Clinical Scientific-Practical Center of Special Types of Medical Care (Oncology); St. Petersburg National Research Academic University of Russian Academy of Sciences
St. Petersburg National Research Academic University of Russian Academy of Sciences
N.N.Petrov Research Institute of Oncology
St. Petersburg National Research Academic University of Russian Academy of Sciences
##article.numberofdownloads## 41
##article.numberofviews## 159
PDF (Русский)

Keywords

breast cancer
predictive markers
prognostic markers
subtypes

How to Cite

, , , , & . (2016). Current possibilities of clinical applications of breast tumors typing expression. Voprosy Onkologii, 62(1), 31–34. https://doi.org/10.37469/0507-3758-2016-62-1-31-34
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Whole-genome expression analysis methods significantly clarified contemporary breast cancer classification. Besides today clinical practice lacks the use of expression methods due to complexity of conduction, analysis and lack of clinical application. Further studies of breast cancer expression characteristics and clinical trials with stratification based of phonotypical features may improve the results of existing anticancer agents. Creation of limited clinically applicable test system, which incorporates all the specific breast cancer subtypes is currently needed.
https://doi.org/10.37469/0507-3758-2016-62-1-31-34
##article.numberofdownloads## 41
##article.numberofviews## 159
PDF (Русский)

References

Моисеенко Ф. В., Бужинский И., Александров А. и др. Гетерогенность РЭ/РП+НЕЯ2+ рака молочной железы // 1-й Российский онкологический научно-образовательный форум с международным участием «Белые Ночи - 2015». Сборник тезисов. - 2015. - С. 97.

Bastien R.R., Rodriguez-Lescure A., Ebbert M.T. et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers // BMC Med Genomics. - 2012. - Vol. 5. - P. 44.

Burstein M.D., Tsimelzon A., Poage G.M., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer // Clin Cancer Res. - 2015. - Vol. 21 (7). - P. 1688-1698.

Carey L.A., Dees E.C., Sawyer L. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes // Clin Cancer Res. - 2007. - Vol. 13 (8). - P. 2329-2334.

Cheang M.C., Martin M., Nielsen TO. et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression // Oncologist. - 2015. - Vol. 20 (5). - P. 474482.

Creighton C.J. The molecular profile of luminal B breast cancer // Biologics. - 2012. - Vol. 6. - P. 289-297.

Fendly B.M.,Winget M., Hudziak R.M. et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product // Cancer Res. - 1990. - Vol. 50 (5). - P. 1550-1558.

Gruvberger S., Ringner M., Chen У et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns // Cancer Res. - 2001. - Vol. 61 (16). - P. 5979-5984.

Habel L.A., Shak S., Jacobs M.K. et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients // Breast Cancer Res. - 2006. - Vol. 8 (3). -P. R25.

Jensen E.V., Desombre E.R., Hurst D.J. et al. Estrogen-receptor interactions in target tissues // Arch Anat Microsc Morphol Exp. - 1967. - Vol. 56 (3). - P. 547-569.

Lehmann B.D., Bauer J.A., Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies // J Clin Invest. - 2011. - Vol. 121 (7). - P. 2750-2767.

McGuire W.L. Estrogen receptors in human breast cancer // J Clin Invest. - 1973. - Vol. 52 (1). - P. 73-77.

Nadji M., Gomez-Fernandez C., Ganjei-Azar P. et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers // Am J Clin Pathol. - 2005. - Vol. 123 (1). - P. 21-27.

Parker J.S., Mullins M., Cheang M.C. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes // J Clin Oncol. - 2009. - Vol. 27 (8). - P. 1160-1167.

Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumours // Nature. - 2000. - Vol. 406 (6797). - P. 747-752.

Prat A., Parker J.S., Karginova O. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer // Breast Cancer Res. - 2010. - Vol. 12 (5). - P. R68.

Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 // N Engl J Med. - 2001. - Vol. 344 (11). - P. 783-792.

Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications // Proc Natl Acad Sci U S A. - 2001. - Vol. 98 (19). - P. 10869-10874.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...